AZ Sustains Strong China Growth Via Commercial Innovation

AstraZeneca’s strong showing in China in the third quarter was driven by a combination of expanded coverage, investment in patient access efforts and an innovative commercial model. New introductions Tagrisso and Farxiga are also expected to add to the momentum.